Status:
COMPLETED
The Copenhagen Analgesic Study
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Gonad Regulating Hormone Adverse Reaction
Analgesic Adverse Reaction
Eligibility:
All Genders
18+ years
Brief Summary
Fundamental aspects of reproductive function are established in fetal life and there is a present increased awareness of the potential effects of fetal exposures on reproductive health of offspring. E...
Detailed Description
Fetal gonadal development is essential for adult reproductive health. Experimental studies strongly suggest that maternal use of mild analgesics (e.g. paracetamol and non-steroidal anti-inflammatory d...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Infants:
- Singleton pregnancies
- Term pregnancy (week 37+0 to 42+0)
- Parents:
- Maternal and paternal Caucasian origin
- Maternal pre-pregnancy BMI between 18 and 35 kg/m2
- Exclusion criteria:
- Infants:
- • Fetal malformations or chromosomal disorders
- Parents:
- Serious maternal illness, including pre-existing maternal diabetes or thyroid gland diseases
- Gestational diabetes
Exclusion
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2022
Estimated Enrollment :
685 Patients enrolled
Trial Details
Trial ID
NCT04369222
Start Date
March 1 2020
End Date
November 30 2022
Last Update
July 10 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Growth and Reproduction, Rigshospitalet
Copenhagen, Denmark, 2100
2
Department of Obstetrics and Section of fetal medicine, Rigshospitalet
Copenhagen, Denmark, 2100